We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

57 hedge funds and large institutions have $71M invested in Viridian Therapeutics in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

0.05% less ownership

Funds ownership: 2.5% → 2.45% (-0.05%)

2% less capital invested

Capital invested by funds: $72.5M → $71M (-$1.47M)

3% less funds holding

Funds holding: 59 → 57 (-2)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

Holders
57
Holders Change
-2
Holders Change %
-3.39%
% of All Funds
1.3%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
22
Reduced
12
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.26M
2
OM
Opaleye Management
Massachusetts
+$1.23M
3
BWP
BSW Wealth Partners
Colorado
+$1.02M
4
SG Americas Securities
SG Americas Securities
New York
+$583K
5
State Street
State Street
Massachusetts
+$420K

Top Sellers

1
6CM
683 Capital Management
New York
-$3.21M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.11M
3
Millennium Management
Millennium Management
New York
-$185K
4
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$142K
5
SIM
Spark Investment Management
New York
-$64K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$21.4M -$3.11M -32,987 -11%
BWP
2
BSW Wealth Partners
Colorado
$9.29M +$1.02M +10,849 +732%
BlackRock
3
BlackRock
New York
$7.88M +$121K +1,285 +1%
OM
4
Opaleye Management
Massachusetts
$7.79M +$1.23M +13,047 +16%
Vanguard Group
5
Vanguard Group
Pennsylvania
$4.82M -$56.1K -595 -1%
AG
6
Artal Group
Luxembourg
$2.79M – – –
State Street
7
State Street
Massachusetts
$2.08M +$420K +4,458 +22%
JP Morgan Chase
8
JP Morgan Chase
New York
$2.03M +$44.9K +476 +2%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$2.01M +$2.26M +24,000 New
Northern Trust
10
Northern Trust
Illinois
$1.55M +$18.2K +193 +1%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.22M +$59.5K +631 +5%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$1.19M -$14.4K -153 -1%
KCM
13
Kennedy Capital Management
Missouri
$959K -$11.6K -123 -1%
SG Americas Securities
14
SG Americas Securities
New York
$517K +$583K +6,177 New
Millennium Management
15
Millennium Management
New York
$495K -$185K -1,962 -25%
TCIM
16
TIAA CREF Investment Management
New York
$463K -$57.8K -613 -10%
BW
17
Biegel & Waller
Maryland
$371K – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$350K +$17.8K +189 +5%
Deutsche Bank
19
Deutsche Bank
Germany
$328K +$61.7K +654 +20%
Morgan Stanley
20
Morgan Stanley
New York
$282K -$30.4K -322 -9%
Charles Schwab
21
Charles Schwab
California
$268K – – –
California State Teachers Retirement System (CalSTRS)
22
California State Teachers Retirement System (CalSTRS)
California
$219K – – –
OAM
23
Oxford Asset Management
United Kingdom
$218K +$248K +2,626 New
Goldman Sachs
24
Goldman Sachs
New York
$212K -$50.4K -534 -17%
TA
25
Teachers Advisors
New York
$186K -$1.51K -16 -0.7%
1
2 3

VRDN Hedge Fund Activity: Q3 2018 in Review

57 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2018, worth a combined $71M — down 2% from $72.5M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of VRDN and 7 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 22 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.26M. The largest seller was 683 Capital Management, exiting entirely with an estimated $3.21M sold.

  • 57 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2018, down from 59 in Q2 2018.
  • Funds reported $71M of Viridian Therapeutics stock for Q3 2018, down 2% quarter-over-quarter.
  • 7 funds opened new Viridian Therapeutics positions in Q3 2018 and 9 closed out, a net change of -2 holders.
  • The largest Viridian Therapeutics buyer in Q3 2018 was Point72 Asset Management, an estimated $2.26M added.
  • The largest Viridian Therapeutics seller in Q3 2018 was 683 Capital Management, an estimated $3.21M sold.

Based on aggregated 13F filings for Q3 2018.